Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol-Myers Squibb news coverage encompasses regulatory developments, clinical trial results, product launches, business transactions, and corporate initiatives. The company's activities across oncology, hematology, immunology, cardiovascular, and neuroscience generate frequent updates that impact stakeholders in the healthcare and investment communities.
Regulatory announcements represent significant news events for Bristol-Myers Squibb, including approvals of new medicines, expanded indications for existing products, and regulatory submissions in various markets. These milestones reflect the progression of the company's pipeline from clinical development through regulatory review to market authorization. Priority review designations, breakthrough therapy designations, and orphan drug designations also generate news coverage as indicators of regulatory progress.
Clinical trial data releases occur at medical conferences, in peer-reviewed publications, and through corporate announcements. Results from pivotal trials evaluating new medicines or expanded uses of approved products receive particular attention from the medical community and investors. The company's extensive clinical trial portfolio across multiple therapeutic areas produces a steady stream of data readouts that inform understanding of product profiles and market potential.
Business development activities including acquisitions, licensing agreements, research collaborations, and strategic partnerships shape Bristol-Myers Squibb's long-term direction. These transactions can bring new assets into the pipeline, provide access to novel technologies, or establish collaborations with academic institutions and biotechnology companies. Divestitures and portfolio prioritization decisions also generate news coverage.
Commercial performance updates occur through periodic financial reporting and corporate presentations. These updates provide insight into product uptake, market penetration, competitive dynamics, and the impact of healthcare policy changes on business results. Manufacturing capacity expansions, supply chain developments, and commercial launches in new geographic markets represent additional categories of business news.
Corporate initiatives related to sustainability, patient access, health equity, research funding, and community engagement reflect broader aspects of Bristol-Myers Squibb's operations beyond drug development and commercialization. Leadership changes, organizational restructuring, and strategic priority shifts also contribute to news flow.
Bristol Myers Squibb (NYSE: BMY) announced a significant presence at the 63rd ASH Annual Meeting, showcasing research on hematologic diseases, including data from over 80 studies. Key presentations include results from the Phase 3 TRANSFORM study of Breyanzi (lisocabtagene maraleucel) against standard care for relapsed or refractory large B-cell lymphoma and new findings on CELMoD therapies like iberdomide. The company highlights its commitment to innovation in treatments for multiple myeloma, lymphoma, and myeloid diseases aimed at improving patient outcomes.
Bristol Myers Squibb (NYSE:BMY) showcased its commitment to rheumatology by presenting significant data on Orencia and deucravacitinib at the American College of Rheumatology (ACR) Convergence 2021. The presentations covered 29 studies, with key findings revealing that patients treated with Orencia showed improved disease activity scores in rheumatoid arthritis, especially among seropositive patients. Additionally, deucravacitinib, an oral TYK2 inhibitor, demonstrated promising results in the treatment of psoriatic arthritis, highlighting the company’s focus on innovative therapies for immune-mediated diseases.
Bristol Myers Squibb (NYSE:BMY) reported third quarter 2021 revenues of $11.6 billion, marking a 10% year-over-year increase. The GAAP earnings per share (EPS) was $0.69, a 16% decline, while non-GAAP EPS rose 23% to $2.00. The company's growth was driven by strong sales of Revlimid, Eliquis, and new products. Key regulatory advancements include FDA priority review for the relatlimab and nivolumab combination in melanoma. Updated full-year guidance indicates a reduction in GAAP EPS expectations to $2.68 - $2.83 and non-GAAP EPS to $7.40 - $7.55.
Bristol Myers Squibb (BMY) has announced a rescheduled earnings conference call to discuss its third quarter 2021 results. The call will take place on October 27, 2021, at 10:00 a.m. ET. Company executives will review financial results and address investor inquiries. A live webcast of the call will be accessible at investor.bms.com, and a replay will be available from 1:30 p.m. ET on October 27 through 1:30 p.m. ET on November 10, 2021.
Bristol Myers Squibb has received European Commission approval for its drug Opdivo (nivolumab) in combination with chemotherapy for the first-line treatment of adult patients with HER2-negative, advanced gastric cancers. This approval is based on the successful Phase 3 CheckMate -649 trial, showing a significant improvement in overall survival (14.4 months vs. 11.1 months) and progression-free survival (8.31 months vs. 6.05 months) compared to chemotherapy alone. The treatment is now available across the EU and in additional countries, benefiting patients with specific tumor characteristics.
Dr. Reddy’s Laboratories has received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules in 2.5 mg and 20 mg strengths, with tentative approvals for other strengths. This positions the company to gain 180 days of generic drug exclusivity for these products. The approval follows a settlement with Celgene (Bristol Myers Squibb) regarding REVLIMID® patents, which also allows Dr. Reddy’s to market generic versions starting from January 31, 2026. This development aims to provide a more affordable option for patients.
Bristol Myers Squibb announced that the CHMP of the EMA has recommended approval for Zeposia (ozanimod) to treat adults with moderately to severely active ulcerative colitis. This recommendation is based on positive results from the Phase 3 True North study, which showed substantial improvements in multiple clinical endpoints. If approved by the European Commission, Zeposia will be the first oral S1P receptor modulator available for ulcerative colitis in the EU. The U.S. FDA previously approved Zeposia for the same condition in May 2021.
Bristol Myers Squibb (NYSE: BMY) announced promising interim results from the Phase 3 DAYBREAK trial, focusing on the long-term efficacy of Zeposia (ozanimod) for relapsing forms of multiple sclerosis (MS). Key findings revealed a low annualized relapse rate (ARR) of 0.103, with over 70% of participants relapse-free after four years. Safety profiles remained consistent with earlier studies, with no new safety signals emerging. The data emphasizes Zeposia's role in early intervention for MS patients, showcasing its potential in improving long-term outcomes.
Bristol Myers Squibb (NYSE: BMY) announced that the Phase 2 LATTICE-UC study for deucravacitinib, a selective TYK2 inhibitor for moderate to severe ulcerative colitis, failed to meet its primary endpoint of clinical remission at Week 12, as well as secondary endpoints. Despite this, the drug's safety profile remained consistent with earlier studies, showing no new safety signals. The company plans further evaluation in a second Phase 2 trial with higher doses. Notably, they maintain a revenue target of over $4 billion for deucravacitinib by 2029.
Bristol Myers Squibb (NYSE: BMY) announced an Investor Event scheduled for November 16, 2021, at 9:30 a.m. ET in New York City. Giovanni Caforio, CEO, will discuss the company’s strategy, pipeline, and business opportunities with the leadership team. This event will be webcast, allowing broader access to the discussion. Materials related to the presentation will be available at the webcast's start, and a replay will be accessible afterward. Bristol Myers Squibb is committed to developing innovative medicines for serious diseases.
FAQ
What is the current stock price of Bristol-Myers Squibb Co (BMY)?
What is the market cap of Bristol-Myers Squibb Co (BMY)?
